Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. حسب Peiqi Yin (6533747)

Expression of lipid biosynthetic genes is decreased with polyamine depletion. حسب Yazmin E. Cruz-Pulido (20285238)

الموضوعات:

Lens profiles as Ez (orange lines) force was increased and Az and Pz (green lines) forces were decreased. حسب Ronald A. Schachar (16674576)

Effective contact rate over time for the different modelling scenarios considered: fixed, continuously increasing, continuously decreasing and with a step-decrease. حسب Joshua Looker (21390948)

"…<p>Effective contact rate over time for the different modelling scenarios considered: fixed, continuously increasing, continuously decreasing and with a step-decrease.</p>…"

The decreased permeability caused by phospholipid content in the membrane could drive the emergence of other functions in the protocells. حسب Wentao Ma (326530)

Disturbance of coherent behaviour leads to a decrease in information transfer. حسب Hannah Zoller (19688084)

LBM-based approach using synchronous transformation with a time step of 0.43s, PNGM-based method using asynchronous transformation with a 5s time step, VGA using explicit scheme wi... حسب Mouad Klai (20818364)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات: